PAR.AU · Paradigm Biopharmaceuticals Limited

-

Please sign in to comment on PAR.AU

1 Comment

Admin

4 years, 1 month ago

Paradigm Biopharmaceuticals Limited is currently in a long term downtrend where the price is trading 19.0% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Paradigm Biopharmaceuticals Limited's total revenue sank by 69.2% to $254K since the same quarter in the previous year.

Its net income has dropped by 306.2% to $-21M since the same quarter in the previous year.

Finally, its free cash flow fell by 217.1% to $-10M since the same quarter in the previous year.

Based on the above factors, Paradigm Biopharmaceuticals Limited gets an overall score of 1/5.

CurrencyCode	AUD
ISIN	AU000000PAR5
Exchange	AU
Industry	Biotechnology
Sector	Healthcare

Market Cap	117M
PE Ratio	None
Beta	0.5
Target Price	0.915
Dividend Yield	None

ABOUT

Paradigm Biopharmaceuticals Limited

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.

PAR.AU · Paradigm Biopharmaceuticals Limited

-

Paradigm Biopharmaceuticals Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Paradigm Biopharmaceuticals Limited using a moving average strategy